On May 28, 2024, Amplitude Ventures announced it closed $263 million in its second venture capital fund for precision medicine. Through this fund, the company plans to continue investing in new precision medicine companies with an interest in biology and artificial intelligence. This fund is backed by existing investors BDC Captial, RBC, Alberta Enterprise Corporation Investissement Québec, Fonds de solidarité FTQ, Fondaction, Teralys Capital, and Venture Ontario and new investors including NorthLeaf Capital Partners, InBC, Finchley Healthcare Ventures, and the Government of Canada’s Venture Capital Catalyst Initiative (VCCI) which is under BDC Capital through its Life Sciences Stream.
Amplitude Ventures, headquarted in Montreal is an investment firm that focuses on the health and life sciences industry.
Osler, Hoskin & Harcourt LLP advised Amplitude Ventures with a team consisting of Chima Ubani and Elisabeth Novak and Stefane Manolakis (Emerging and High Growth Companies) and Alain Fournier (Tax).
Key Contact
Partner, Emerging and High Growth Companies, Montréal
Team
Associate, Emerging and High Growth Companies, Montréal
Associate, Emerging and High Growth Companies, Montréal
Partner, Tax, Montréal
